Compass Pathways announced the establishment of the first Treatment-Resistant Depression Awareness Day in the U.S. on October 14, 2026.

Overview Debates Related claims Topics Sources

In England, estimated financial costs from adverse childhood experiences were £37.8 billion for mental illness and £22.7 billion for smoking, while in Wales each accounted for £1.8 billion.

The American College of Obstetricians and Gynecologists noted that more than one in three perimenopausal and postmenopausal women report depressive symptoms

The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.

In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.

Compass Pathways CEO Kabir Nath stated on October 14, 2026, that the company plans to complete its rolling FDA submission for COMP360 synthetic psilocybin treatment in the fourth quarter of 2026.

Treatment-resistant depression is estimated to affect approximately 4 million people in the U.S., with fewer than 5% receiving a treatment indicated for the condition.

A survey commissioned by Compass Pathways revealed that nearly two in three caregivers report treatment-resistant depression impacts family health, with over half experiencing a major toll on their own mental health.

A survey commissioned by Compass Pathways found that nearly 95% of individuals living with treatment-resistant depression describe themselves as functioning but struggling, surviving day-to-day, or barely getting by.

Approximately one in six Americans take an antidepressant medication, and average duration of use has surpassed five years.

Outro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.

Research led by Dr. Mark Horowitz found that four in five long-term antidepressant users were unable to stop taking their medications due to withdrawal symptoms.

FDA approval standards based on short-term trials adequately protect long-term antidepressant users

Antidepressant medications were originally approved by the FDA based on 8-to-12-week clinical studies despite widespread long-term usage.

The UK government-commissioned review, led by Professor Peter Fonagy, found that approximately one in four people aged 16 to 24 in the UK reports a common mental health problem, such as anxiety or depression

The Lancet review found consistent associations between problematic digital media use and increased risks of depression, anxiety, and sleep disruption in young people.

Researchers are using optogenetics in animal models to study the cellular mechanisms of schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, depression, and addiction

Idiopathic nephrotic syndrome is frequently diagnosed in childhood, and its unpredictable relapses can cause anxiety, depression, and reduced self-esteem in young patients.

Previous studies have found that wildfires and other environmental crises can cause long-term human health impacts, including lung issues and depression.

Alopecia areata in pediatric patients is associated with increased rates of anxiety and depression, representing a significant psychiatric burden during adolescence.